Share Article
With this transition, Gilead’s cardiovascular research and development
organization will report to
“Lou has played an integral role in the newly combined Gilead
organization, helping us achieve significant progress with integration
of our cardiovascular R&D operations. In his new role, Lou will continue
to provide valuable insight and input into our research and development
programs in cardiovascular disease,” said
About
This press release includes forward-looking statements, within the
meaning of the Private Securities Litigation Reform Act of 1995, that
are subject to risks, uncertainties and other factors, including the
risks related to our ability to advance product candidates in our
pipeline. These risks, uncertainties and other factors could cause
actual results to differ materially from those referred to in the
forward-looking statements. The reader is cautioned not to rely on these
forward-looking statements. These and other risks are described in
detail in Gilead’s Annual Report on Form 10-K for the year ended
For more information on Gilead, please call the
Source:
Gilead Sciences, Inc.Susan Hubbard, 650-522-5715 (Investors)Amy Flood, 650-522-5643 (Media)
Investors
Jacquie Ross
investors_relations@gilead.com
Media Contact
Meaghan Smith
public_affairs@gilead.com
Other News
Some of the content on this page is not intended for users outside the U.S.